StrideBio is based on research conducted at University of North Carolina at Chapel Hill and University of Florida.
US-based gene therapy developer StrideBio closed a $15.7m series A round yesterday backed by pharmaceutical firm Takeda, biopharmaceutical company UCB and life science real estate developer Alexandria Real Estate Equities.
The oversubscribed round was led by venture capital firm Hatteras Venture Partners. The corporates took part through their respective corporate venturing subsidiaries Takeda Ventures, UCB Ventures and Alexandria Venture Investments.
Founded in 2015, StrideBio is working on gene therapies that overcome pre-existing neutralising antibodies and improve gene transfer efficiency.
The…